Making Sure Biomarker Testing Is Available and Used for Everyone, Everywhere – Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn about a paper by Matthew P. Smeltzer et al. published in the Journal of Thoracic Oncology:
“43% of clinicians say lung cancer treatment often starts before biomarker results are back.
The latest global International Association for the Study of Lung Cancer survey (1,677 responses from 90 countries) shows improvement since 2018, but also highlights just how far we still have to go.
- Barriers like cost, turnaround time, access, and awareness are still blocking timely testing.
- European participation was high – so this data is especially relevant here.
If biomarker testing is key to personalised lung cancer treatment, we need to make sure it’s available and used for everyone, everywhere.”
Title: The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing
Authors: Matthew P. Smeltzer, Jennifer C. King, Casey Connolly, Kristin Brunson, Maiyan Chau, Shuyan Chen, Anna Kerpel-Fronius, Sylvie Lantuejoul, Anant Mohan, Allison Plaxco, Upal Basu Roy, Ricardo Santos, Ross Soo, Gavitt Woodard, Murry W. Wynes, Yasushi Yatabe, Amanda Young, Karen Kelly
You can read the Full Article in the Journal of Thoracic Oncology.
More posts featuring Lung Cancer Europe.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023